Skip to content
Review

Alcohol-induced dysregulation of tau and acetylation pathways in the pathogenesis of Alzheimer's disease.

Sep 2026 · Neuroscience · Vol 615, pp. 447-461 · 0 citations · 161 references
Medicine

TL;DR

Understanding the molecular mechanisms that link alcohol consumption, acetylation dysregulation, and tau pathology has significant therapeutic potential in AD treatment.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder whose global prevalence is rapidly increasing, highlighting the urgent need to identify modifiable risk factors. Chronic alcohol consumption has emerged as one such significant factor contributing to the risk and progression of AD. Importantly, alcohol metabolism impacts cellular acetylation pathways, creating an environment that promotes protein dysregulation and disrupts cellular functions. Among these alterations, tau acetylation has garnered attention as a crucial post-translational modification that accelerates tau pathology, impairs tau clearance, and facilitates the formation of neurofibrillary tangles (NFTs), the key hallmarks of AD. Growing evidence indicates that chronic alcohol consumption leads to disruptions in acetyl-CoA homeostasis, NAD+ pathways, dysregulation of acetyltransferase, sirtuin activity, and epigenetic aberrations promoting abnormal tau acetylation and neurodegeneration. Thus, understanding the molecular mechanisms that link alcohol consumption, acetylation dysregulation, and tau pathology has significant therapeutic potential in AD treatment.

View source

Similar papers

Review Oct 2026

Targeting tau acetylation in Alzheimer's disease: Molecular mechanisms, pathological consequences, and therapeutic opportunities of dietary phytochemicals.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by cognitive decline, synaptic dysfunction, and neuronal loss. Emerging evidence identifies tau acetylation as a crucial post-translational modification that contribute significantly to tauopathies associated pathology in AD. Aberrant ta...

K. Basavaraju, Poornima Priyadarshini · 0 citations
Review Open access Sep 2026

Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities

Background: Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder and a leading cause of dementia, involving the gradual loss of cognitive function, memory, and neurons. While the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs), caused by hyperphosphorylation of the protein...

Amanpreet Kaur, Geeta Aggarwal, Vetriselvan Subramaniyam · 0 citations
Review Open access Sep 2026

Translating Molecular Pathogenesis into Therapeutics: Emerging Strategies and Clinical Prospects for Alzheimer’s Disease

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...

Mona Piplani, Shivani Thakur, Pankaj Kumar et al. · 0 citations
Review Open access Aug 2026

Genetic and physiological basis of Alzheimer’s disease: A review

The current understanding of the genetic and physiological mechanisms underlying Alzheimer’s disease is reviewed and modern approaches for diagnosis and treatment are discussed.

Zahraa Mohammed Fakheir, S. A. H. Jasim · 0 citations
Review 2026

Epigenetic modulators as therapeutics for neurodegenerative disorders/Alzheimer's disease.

Overall, epigenetic modulators present a promising therapeutic approach for neurodegeneration, and continued research integrating various assays like DNA methylation analysis, histone modification analysis, non-coding RNA analysis, neuroinflammation analysis, and functional and behavioral assays in AD models is signifi...

Debojyoti Halder, Denish Prajapati, Tonmoy Banerjee et al. · 0 citations
Review Open access Jul 2026

Emerging therapeutic targets beyond amyloid and tau in Alzheimer's Disease: Implications for lifestyle, metabolism and preventive medicine.

Current evidence on emerging treatment strategies beyond the classical amyloid and tau paradigm is summarized, with particular emphasis on microglial activation, mitochondrial function, autophagy, and lipid homeostasis.

Nataliya V. Izhytska, Katazyna Anna Sobczyk, Karolina Ogrodnik et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.